Ryan & Maniskas, LLP ( www.rmclasslaw.com/cases/prx ) is investigating potential claims against the board of directors of Par Pharmaceutical Companies Inc. ("Par Pharmaceutical" or the "Company") PRX +0.02% concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell Par Pharmaceutical to an affiliate of TPG in a transaction valued at approximately $1.9 billion.
Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company's board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Par Pharmaceutical. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/prx .
Under the terms of the transaction, Par Pharmaceutical shareholders will receive $50.00 per share of Par Pharmaceutical stock they own.
No comments:
Post a Comment